Biomarker Research (May 2021)

Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia

  • Jayna J Mistry,
  • Charlotte Hellmich,
  • Amelia Lambert,
  • Jamie A Moore,
  • Aisha Jibril,
  • Angela Collins,
  • Kristian M Bowles,
  • Stuart A Rushworth

DOI
https://doi.org/10.1186/s40364-021-00291-y
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML.